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Abstract
Introduction Our aim was to evaluate the relationship of
patients' age to histopathological features of hereditary breast
tumours in a series of breast cancer families not selected for age
at diagnosis. In sporadic breast cancer, tumours from
premenopausal patients have been shown to differ from those of
postmenopausal patients, but this phenomenon has been little
studied among familial patients.
Methods Representative areas of all available breast cancer
tissue specimens (n = 262) from 25 BRCA1, 20 BRCA2, and
74 non-BRCA1/2 breast cancer families were punched into a
tissue microarray. Immunohistochemical staining of oestrogen
receptor, progesterone receptor, ERBB2, and p53 as well as
the histology and grade of tumours in these three groups of
families were studied in different age groups and compared with
each other.
Results We found that only breast cancers from young (<50
years)  BRCA1+  patients represent features documented as
being typical of BRCA1-associated cancers, such as high
tumour grade, negativity for oestrogen and progesterone
receptors, and overexpression of p53. Among the BRCA2
families, the opposite was found, with a significantly higher
frequency of tumours negative for oestrogen and progesterone
receptors among the older patients than among the other
groups, but no distinctive tumour characteristics among the
younger BRCA2 patients.
Conclusion Tumours of BRCA1 and BRCA2 carriers aged 50
years or more differed significantly from those of younger
carriers. This difference may reflect different biological
behaviour and pathways of tumour development among the
older and the younger BRCA1  and  BRCA2  patients, with
impact also on prognosis and survival.
Introduction
Distinct pathological features among BRCA1-associated
tumours have been found when such tumours are compared
with sporadic cancers; these features include high tumour
grade, negativity for oestrogen receptor (ER), overexpression
of p53, negativity for progesterone receptor (PR), and a higher
proportion of medullary and atypical medullary carcinomas [1-
3]. Recently, cDNA expression analyses have suggested a
basal epithelial phenotype for BRCA1 tumors [4] and expres-
sion of cytokeratins 5/6 have been associated with BRCA1
tumours [5]. Among BRCA2-associated tumours, findings
have been inconsistent, and in most cases no significant dif-
ference has been found between BRCA2-associated and
sporadic cancers [1,2,6,7].
In our previous report [8], we have shown, consistent with ear-
lier studies, that BRCA1-associated cancers were diagnosed
younger and were more ER- and progesterone-receptor-nega-
tive (PR-), more p53+, and of higher grade than unselected
breast tumours or tumours from non-BRCA1/2 breast cancer
families. However, in multivariate analysis the independent fac-
tors, as compared with non-BRCA1/2 tumours, were age of
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diagnosis, grade, and PR-negativity. BRCA2 cases did not
have such distinctive features compared with non-BRCA1/2
cases.
In large studies on sporadic breast cancer tumours, tumours
from premenopausal patients have been shown to differ from
those of postmenopausal patients [9-11], but this has been lit-
tle studied among familial patients. In this study, we had an
excellent opportunity to study familial cases without age
restriction and to evaluate whether the histology and immuno-
histochemistry differ in the different age groups (according to
whether age of diagnosis is below or over 50 years, with age
being used as a surrogate for menopause status) among
BRCA1, BRCA2, and non-BRCA1/2 families.
Materials and methods
Family history of cancer was screened for among breast can-
cer patients in the Department of Oncology, Helsinki Univer-
sity Central Hospital [12]. Families were collected with a
simple criterion of at least three first- or second-degree rela-
tives with breast or ovarian cancer, with no restriction regard-
ing age. All the families were tested for BRCA1 and BRCA2
mutations by mutation analysis of the whole coding sequences
and exon/intron boundaries of the genes as described else-
where [13,14], or were tested for all 18 previously reported
Finnish BRCA1 and BRCA2 mutations [13-16]. In this study,
as previously described [8], we collected all the available par-
affin-wax blocks of the primary breast cancers (n = 262) from
119 breast cancer families. Altogether, 51 cancers from the
25 BRCA1 families, 59 cancers from the 20 BRCA2 families,
and 152 cancers from the 74 non-BRCA1/2 families were
obtained.
The patients' median age at diagnosis of the tumours was 44
years for BRCA1, 47 years for BRCA2, and 55 years for non-
BRCA1/2. For comparison of tumours from premenopausal
and postmenopausal patients, the age of 50 years was chosen
as a surrogate for menopause. Among the BRCA1 patients,
34 (66.7%) were diagnosed when they were below 50 years
of age (median age 39) and 17 (33.3%) when they were 50 or
more (median age 55); the respective numbers among
BRCA2 patients were 35 (59.3%) and 24 (40.7%) (median
ages 39 and 56.5, respectively), and among non-BRCA1/2
patients, 58 (38.2%) and 94 (61.8%) (median ages 44 and
65, respectively).
The most representative area of the tumour was punched to
produce a hereditary breast cancer tissue microarray including
two cores (diameter 0.6 mm) from all the original blocks as
described elsewhere [8,17]. The use of microarray tissue
blocks makes it possible to stain all the samples at the same
time and in the same conditions. Subgroups of the material are
therefore very well comparable, and a highly significant corre-
lation between this kind of multicore system and studying the
whole sections of the original blocks has also been shown
[18,19].
All the tissue microarray slides were stained with routine meth-
ods used for pathological diagnostics with ER, PR, ERBB2,
and p53 antibodies in the same laboratory [8]. Briefly, five-
micrometer sections were cut from paraffin-embedded blocks,
dewaxed in xylene, and dehydrated in a series of graded alco-
hols. The sections were pretreated in a microwave oven and
incubated with antibody overnight. ER antibody (1:50) and
ERBB2 antibody (NCL-CB11, 1:400) were purchased from
Novocastra (Newcastle upon Tyne, UK), and PR (1:250) and
p53 antibodies (1:100) were from Dako (Copenhagen, Den-
mark). The evaluation of the staining results was similar to that
used in routine diagnostics, and samples were considered
positive when 10%, 10%, and 20% of the cells were stained
with ER, PR, and p53, respectively. Samples having a moder-
ate or intense staining of the entire membrane in more than
10% of the tumour cells (immunohistochemical scores of 2+
and 3+) were considered to be ERBB2+. Other staining pat-
terns (0 and 1+) were considered to be negative. We studied
the haematoxylin-and-eosin sections of the original blocks to
achieve histological diagnosis and grading (all by the same
pathologist (PH)). Statistical analysis was done with SPSS
version 8.0 for Windows. We tested the differences in dichot-
omous variables with a χ2 or Fisher's exact test. All P values
are two-tailed.
Permissions for this study were obtained from the ethics com-
mittees of the Department of Oncology and the Department of
Obstetrics and Gynaecology, Helsinki University Central Hos-
pital, and of the Ministry of Social Affairs and Health in Finland.
Blood and tumour samples were used in this study with the
informed consent of the probands and of the family members.
Results
In BRCA1 families, patients whose cancer was diagnosed
when they were under 50 years of age differed significantly
from those diagnosed at 50 years or older in the presence of
grade 3 tumours (84.4% vs 47.1%, P = 0.009), ER-negativity
(83.3% vs 25%, P = 0,001), and p53-positivity (50.0% vs
7.7%, P = 0.014) (Table 1). All of the five cancers with med-
ullary histology were also detected in patients under 50 years
old. Patients who were BRCA1+ and were under 50 years old
at diagnosis differed significantly in all of these factors from
familial non-BRCA1/2  patients (proportion of grade 3
tumours, 84.4% vs 17.3%, respectively, P ≤ 0.0005; of ER-
negativity, 83.3% vs 29.3%, P  ≤ 0.0005; of PR-negativity,
90.3% vs 31.0%, P ≤ 0.0005; and of p53-positivity, 50.0% vs
25.9%, P = 0.024). However, patients from BRCA1 families
diagnosed at age 50 years or older differed significantly only
for grade from the non-BRCA1/2 patients in the same age
group (47.1% vs 23.3, P = 0.044).Available online http://breast-cancer-research.com/content/7/4/R465
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In BRCA2 families, tumours of patients diagnosed at less than
50 years of age differed significantly from those of the older
patients for ER-negativity (20.6% vs 52.6%, respectively, P =
0.017) and PR-receptor negativity (35.3% vs 80.0%, P  =
0.001) (Table 1). In contrast to BRCA1 tumours, the BRCA2
tumours diagnosed in patients 50 years or older were more
often ER- (52.6% vs 25.6%, P = 0.02) and PR- (80.0% vs
54.4%, P = 0.036) than non-BRCA1/2 cancers among the
same age group. Tumours of patients diagnosed at less than
50 years of age were very similar to non-BRCA1/2 tumours in
the same age group (Table 1).
Pathological features of non-BRCA1/2 tumours did not vary
significantly between the two age groups.
Discussion
In this study, we have evaluated whether tumour histology and
immunohistochemistry are influenced by age of onset (meno-
pause status) among families with BRCA1, BRCA2, or non-
BRCA1/2 tumours. Most of the earlier studies of the charac-
teristics of tumours in BRCA1 and BRCA2 carriers have been
based on young patients only. Because there was no age
restriction in our selection criterion, we had an excellent oppor-
tunity to study patients within the whole age distribution.
In BRCA1 families, tumours from patients diagnosed at over
50 years of age were surprisingly different from those in
BRCA1 carriers diagnosed at under 50 years. Only tumours
from the younger patients exhibited the distinctive characteris-
tics that have been found to be typical of BRCA1 tumours,
with higher grade, negativity for ER and PR, and positivity for
p53 distinguishing them from familial non-BRCA1/2 tumours.
However, tumours from the older patients in BRCA1 families
differed significantly only in grade from tumours in non-
BRCA1/2 patients. There were only five cases among this
older group of patients, for which the BRCA1 mutation status
was unknown. If these patients are excluded from the analysis,
the observed frequencies remain ; therefore those do not
account for the result.
Previously, Vaziri and colleagues [20] have reported that the
tumour immunophenotype of BRCA1-carriers is influenced by
the age of diagnosis. As a control group, those authors used
age-matched breast cancer patients unselected for family his-
tory, whereas in our study we included familial non-BRCA1/2
Table 1
Features of breast tumours according to breast cancer patient's age (years) at diagnosis
BRCA1 tumours BRCA2 tumours Non-BRCA1/2 tumours
Age <50 Age ≥ 50 P < 
0.05a
Age <50 Age ≥ 50 P < 
0.05a
Age <50 Age ≥ 50 P < 
0.05a
Histology
Ductal cancer 24 (70.6) 13 (76.5) 19 (54.3) 18 (75.0) 34 (58.6) 68 (72.3)
Lobular cancer 5 (14.7) 3 (17.6) 12 (34.3) 5 (20.8) 15 (25.9) 15 (16.0)
Medullary cancer 5 (14.7) 2 (3.4) 1 (1.1)
Other cancers 1 (5.9) 4 (11.4) 1 (4.2) 7 (12.1) 10 (10.6)
Grade
I 1 (3.1) 2 (11.8) 7 (23.3) 5 (22.7) 13 (25.0) 33 (36.7)
II 4 (12.5) 7 (41.2) 16 (53.3) 10 (45.5) 30 (57.7) 36 (40.0)
III 27 (84.4) 8 (47.1) 0.009 7 (23.3) 7 (31.8) 9 (17.3) 21 (23.3)
I to II 5 (16.6) 9 (53.0) 13 (76.7) 15 (68.2) 43 (82.7) 69 (76.7)
Immunohistochemistry
ER- 25 (83.3) 3 (25.0) 0.001 7 (20.6) 10 (52.6) 0.017 17 (29.3) 23 (25.6)
ER+ 5 (16.7) 9 (75.0) 27 (79.4) 9 (47.4) 41 (70.7) 67 (74.7)
PR- 28 (90.3) 9 (69.2) 12 (35.3) 16 (80.0) 0.001 18 (31.0) 49 (54.4)
PR+ 3 (9.7) 4 (30.8) 22 (64.7) 4 (20.0) 40 (69.0) 41 (45.6)
p53- 15 (50.0) 12 (92.3) 0.014 27 (81.8) 15 (83.3) 43 (74.1) 75 (81.5)
p53+ 15 (50.0) 1 (7.7) 6 (18.2) 3 (16.7) 15 (25.9) 17 (18.5)
ERBB2- 23 (76.7) 12 (92.3) 29 (83.3) 16 (84.2) 45 (81.8) 64 (83.1)
ERBB2+ 7 (23.3) 1 (7.7) 5 (14.7) 3 (15.8) 10 (18.2) 13 (16.9)
Values are no. (frequency %). aComparison by age group. There were no significant differences according to patients' age in the non-BRCA1/2 
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cancer cases. Vaziri and colleagues observed no differences
in ER or PR staining of tumours between BRCA1  carriers
diagnosed at 50 years or older and controls with sporadic can-
cers [20]. Foulkes and colleagues [21] also recently reported
that the proportion of ER+ tumours increased with patients'
age among the BRCA1 patients included in their study (diag-
nosed at less than 65 years of age), although they found a
strong relationship between BRCA1 carrier status and ER-
negativity of tumours in the age group 55 to 65 years. Vaziri
and colleagues also studied the expression of markers Ki-67,
Cyclin D1, p53, and ERBB2. None of these markers differed
significantly in the patients 50 years or older between BRCA1-
associated cancers and control cancers, although tumours
from the younger BRCA1 age group presented less frequent
ER, PR, and cyclin D1 staining and more frequent Ki-67 and
B-catenin staining than those from control cancers. p53
expression did not differ in their study in different age groups,
nor was p53 more frequently overexpressed among young
BRCA1 patients than in controls.
We did not find the BRCA2-associated tumours to differ sig-
nificantly from familial non-BRCA1/2  tumours among the
younger age group. However, tumours of BRCA2  carrier
patients diagnosed at 50 years or older had more distinctive
features, and were more ER- and PR-, than tumours of younger
patients or tumours of the same age group of BRCA1 patients
or non-BRCA1/2 patients.
The specific features of BRCA1-associated tumours among
the younger age group, and lack of such features among the
BRCA2-associated tumours, are consistent with the overall
characteristics reported previously among BRCA1  and
BRCA2 patients [1,2]. Such features characterise to a large
extent the BRCA1 and BRCA2 tumours overall, as a large
majority (63% in this study) of all breast tumours in the
BRCA1 and BRCA2 families are diagnosed before patients
reach 50 years of age.
However, among both BRCA1 and BRCA2 families, tumours
from older patients form subgroups that are distinctly different
from those of the younger patients. Tumours from the older
BRCA1 patients resemble more those among the mutation-
negative families, or sporadic tumours. The highest incidence
rates and relative breast cancer risk among BRCA1 carriers
are seen before age 50 [22], and some tumours from older
BRCA1 mutation carriers could also be 'sporadic' cancers.
However, the breast tumours from older BRCA1 patients also
differed from mutation-negative ones by their higher grade.
Furthermore, tumours from the older BRCA2 carriers exhib-
ited distinctly different characteristics from the younger ones
or from BRCA1 carrier tumours and mutation-negative ones,
suggesting a strong impact of the germline mutation on
tumour development among the older patients. It is interesting
that the BRCA1 and BRCA2 tumours appear to be opposites
with respect to their characteristics in the age groups of
younger and older patients.
There are now many models and computer programs to test
the probability of BRCA1 or BRCA2 mutations [23-28]. We
have also documented previously that efficient predictors for
BRCA1 and BRCA2 mutations are early age of breast cancer
onset and number of ovarian cancer cases in the family [27].
Simple family history criteria of the strongest predictors (onset
of breast cancer under age 40 and presence of ovarian can-
cer) for a mutation may also provide a rough estimate of a high
likelihood of carrying a mutation [27].
However, it would be useful if, besides family history, his-
topathological markers could also be used to distinguish
patients and families likely to carry a BRCA1/2 germline muta-
tion from mutation-negative families and breast cancer
patients in general. The use of morphologic and immunohisto-
chemical data has been previously suggested to provide a
helpful and cost-effective tool for predicting BRCA1 mutation
among young breast cancer patients [2,29,30]. The findings
here provide further information specifically with respect to
older BRCA1 and BRCA2 patients and warrant further stud-
ies for evaluating the probability of mutation by combining
information on family history and tumour characteristics in the
various age groups.
Conclusion
These findings may reflect different biological behaviour and
pathway of tumour development among the older and the
younger BRCA1 and BRCA2 patients, with impact also on
prognosis and survival. So far, results on survival among
BRCA1 and BRCA2 patients have been inconclusive or con-
tradictory, and large meta-analyses specifically according to
age groups could shed further light on this. Finally, in the con-
text of genetic counselling, specific tumour characteristics
may help evaluate the possibility of a BRCA1 or BRCA2 muta-
tion and the need for mutation testing in a family with a history
of breast cancer. It appears crucial, however, to consider such
features specifically with respect to the age of the patients.
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